Gavin Ha

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index90

i10-index131

Publications388

Citations75,408

Grants

12 total · 4 active

NIH #5R01CA280056-03

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

Active

Amount: $592K
Period: 2023-09-19 → 2028-08-31
PIs: 2
Est. capacity / PI: ~2 students

Awarded at FRED HUTCHINSON CANCER CENTER

NIH #5R01CA280056-02

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

Active

Amount: $567K
Period: 2023-09-19 → 2028-08-31
PIs: 2
Est. capacity / PI: ~2 students

Awarded at FRED HUTCHINSON CANCER CENTER

NIH #1R01CA280056-01A1

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

Active

Amount: $596K
Period: 2023-09-19 → 2028-08-31
PIs: 2
Est. capacity / PI: ~2 students

Awarded at FRED HUTCHINSON CANCER CENTER

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0035

PageRank within Cancer Research co-authorship network

Explore collaboration map

Admission Signals

New paper: Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer (npj Precision Oncology)2026-04-28
New preprint: CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate Cancer2025-10-14
New NIH award: $1,056K — Translating the tumor regulome from cell-free DNA for precision oncology2025-09-01
New NIH award: $592K — Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes2023-09-19
New NIH award: $567K — Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes2023-09-19
New NIH award: $596K — Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes2023-09-19

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0001-7578-7272

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 42

Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer
npj Precision Oncology · 2026-04-28
Abstract LB433: Multi-omic reconstruction of metastatic prostate cancer evolution from rapid autopsy reveals polyclonal seeding and implications for liquid biopsy
Cancer Research · 2026-04-17
Abstract LB006: Prostate cancer phenotypes determined from circulating tumor DNA associate with outcomes to 177Lu-PSMA-617 therapy
Cancer Research · 2026-04-17
Abstract 5322: Non-invasive tracking of clonal evolution and treatment response through liquid biopsies.
Cancer Research · 2026-04-03
Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology
bioRxiv (Cold Spring Harbor Laboratory) · 2026-02-12
Abstract PR005: Epigenetically Informed Therapeutic Strategies for DNA-Hypomethylated Prostate Cancer
Cancer Research · 2026-01-20
Supplementary Table S2 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
2025-12-11
Supplementary Table S5 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
2025-12-11
Supplementary Table S1 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
2025-12-11
Supplementary Figures from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
2025-12-11
Supplementary Table S4 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
2025-12-11
Supplementary Table S3 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
2025-12-11
CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate CancerPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-10-14
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Nature Communications · 2025-10-08 · 4 citations
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
eLife · 2025-09-26 · 1 citations
Author response: Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
2025-09-26
Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology
Journal of Clinical Investigation · 2025-09-16 · 1 citations
2457P CDK12 as a prostate cancer predisposition gene
Annals of Oncology · 2025-09-01
Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
2025-08-25
Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
2025-08-25

Open author page on OpenAlex →

Gavin Ha

Grants

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

All Grants

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes

Translating the tumor regulome from cell-free DNA for precision oncology

Translating the tumor regulome from cell-free DNA for precision oncology

Translating the tumor regulome from cell-free DNA for precision oncology

Predicting transcriptional signatures and tumor subtypes from circulating tumor DNA

Predicting transcriptional signatures and tumor subtypes from circulating tumor DNA

Identifying driver non-coding alterations in metastatic prostate cancer from tumor and cell-free DNA

Identifying driver non-coding alterations in metastatic prostate cancer from tumor and cell-free DNA

Identifying driver non-coding alterations in metastatic prostate cancer from tumor and cell-free DNA

Predicting transcriptional signatures and tumor subtypes from circulating tumor DNA

Career Trajectory

Research Cluster Map

Potential Collaborators

Recent Publications